Site icon Nairametrics

“Top performing states on the Covid-19 mass vaccination in Nigeria”- NPHCDA

Uganda,COVID-19 vaccination

COVID-19 vaccine

The National Primary Health Care Development Agency (NPHCDA) has released the summary of the COVID-19 vaccination progress towards vaccinating all eligible persons in all states in Nigeria, ranking from top-performing states to worst.

The first wave of the Coronavirus Disease 2019 (COVID-19) pandemic in Nigeria began when the first index case was reported on the 27th of February 2020 which was from a 44-year-old Italian citizen who arrived at Muritala Mohammed Airport, Lagos from Milan, Italy.

As of 31st October 2023, 5,708,974 samples have been tested, 266,675 cases have been confirmed, and 259,953 cases have been discharged. There are currently 3,567 active cases and 3,155 deaths.

The mass vaccination

On March 2, 2021, four million doses of Oxford-AstraZeneca Covid-19 vaccine doses from the COVAX initiative arrived in Nigeria and on March 5, the vaccination campaign began. 7 vaccines have been approved for use in Nigeria, 3 of them are approved for clinical trials.

Highlights from NPHCDA

Percentage of fully vaccinated versus partially vaccinated versus unvaccinated in all states in Nigeria.

States in Nigeria  % of fully vaccinated   % of partially vaccinated  % of unvaccinated  
Nasarawa   100  0  0 
Jigawa   100  0  0 
Osun  100  0  0 
Kaduna  100  0  0 
Kano  100  0  0 
Adamawa  100  0  0 
Yobe  99  1  0 
Gombe   93  7  0 
Plateau  89  4  7 
Borno  85  6  9 
Ekiti  84  13  3 
Kwara  81  7  12 
Sokoto  80  16  4 
Niger  79  7  14 
Kebbi  79  12  9 
Imo  73  2  15 
Anambra  71  7  28 
Oyo  65  2  33 
Zamfara  63  15  22 
Enugu  62  6  32 
Abia   61  3  36 
Edo  57  1  42 
Taraba  56  10  34 
FCT  56  11  33 
Bauchi   55  5  40 
Benue   55  12  33 
Cross River  53  7  40 
Katsina   45  9  46 
Akwa Ibom  44  4  52 
Bayelsa  43  3  54 
Ogun  41  7  52 
Lagos  33  4  63 
Ebonyi  31  6  63 
Delta  24  6  70 
Kogi  22  6  72 
Rivers  18  4  80 
Ondo  17  7  76 

 

News continues after this ad

Exit mobile version